The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…)
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission
Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent.
Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ...
MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices supplement.
The article, titled "Investing in innovation for a healthier Canada," is available on page 2 of the Post supplement.
Posted by Elizabeth Monier-Williams, marketing and communications officer.
Joel Liederman, MaRS Innovation's vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post's website.
The chat will take place on June 28, 2012 at 2 pm.
Topic: Why Canada can't do anything with its big ideas
When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada. (more…)
U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.
Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:
Flybits is launching a corporate presence in East London's Tech City, which is also known as the Silicon Roundabout. (more…)
This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.
The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research. (more…)
At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.
The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot ...
BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.
A French version of this release is available via CQDM's website.
This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to ...